生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Ramosetron Hydrochloride, a selective 5-HT3 receptor antagonist, has been on the market as an antiemetic drug for cancer patients receiving chemotherapy or anesthesia. The effective dose of ramosetron (hydrochlorid) to be injected for the near-complete prophylaxis of PONV (Postoperative nausea and vomiting) 6 to 24 hours after surgery in high-risk patients is a 0.6 mg bolus injection at the end of the surgery[2]. Moreover, ramosetron (hydrochlorid) administered during induction of anaesthesia may affect maximal change in QTc interval during off-pump coronary artery bypass surgery[3]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.17mL 0.63mL 0.32mL |
15.83mL 3.17mL 1.58mL |
31.67mL 6.33mL 3.17mL |
参考文献 |
---|